ABTI Alpha-Beta Technology Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ABTI Alpha-Beta Technology

ABTI 0.200

+99,900.0%

Jun 17 12:34 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Cacaito who wrote (326)	7/29/1997 5:05:00 PM
From: gaddis	of 572

Cacaito, The Journal of Biotechnology in Healthcare (Autumn 1995 Volume Two Number Two) summarizes the in vitro and in vivo pre-clinical activities of Betafectin as well as its clinical development. You are right in stating that there are a number of issues involved. I believe that management did an excellent job in formulating the Phase 3 trial and playing to Betafectin's strengths. If Betafectin is a viable biological response modifier, then this trial will show it.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next